The DOI matches its Crossref record; 3 of the 4 references it cites were found in a registry or an index.
Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent breakthroughs with the detection of specific phosphorylated tau fragments in blood, some with apparent high specificity for early AD, are opening new perspectives in this regard 97 .”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [97]
In the citing paper
“Aducanumab, a monoclonal antibody against Aβ aggregates, has obtained the FDA’s approval as an Alzheimer’s drug for its ability to reduce the level of Aβ plaques in patients with early AD or mild cognitive impairment (MCI).46–48”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [47]
In the citing paper
“So far, two antibody-based drugs aducanumab and lecanemab have been approved by the FDA”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [47]
In the citing paper
“Aducanumab is the first FDA-approved therapy for Alzheimer’s.47,48”
From Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future (2023) · cites this paper as [47]
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Andrews, J. S., Desai, U., Kirson, N. Y., Zichlin, M. L., Ball, D. E., & Matthews, B. R. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.06.005 · Cited by 338
Morant, A. V., Jagalski, V., & Vestergaard, H. T. (2019) · Clinical and Translational Science · doi:10.1111/cts.12617 · Cited by 22
Cited by
Sorted by citations
Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future
Zhang, Y., Chen, H., Li, R., Sterling, K., & Song, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01484-7 · Cited by 988
“In June 2021, aducanumab was approved by the FDA for medical use.(47,48) However, it is considered controversial due to the lack of sufficient evidence to support its efficacy.”
BackgroundMethodApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics
Karran, E., & De Strooper, B. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00391-w · Cited by 742
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
The amyloid cascade hypothesis: an updated critical review
Kepp, K. P., Robakis, N. K. R. K., Høilund‐Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 315
Metadata
- Authors
- Alexander, G. C., Emerson, S., & Kesselheim, A. S.
- Affiliations
- Johns Hopkins University (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-05-04
- Volume
- 325
- Issue
- 17
- Pages
- 1717
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3149600507
- Cited by
- 240
- References
- 4
- Citations by year
- 2026: 25 · 2025: 24 · 2024: 41 · 2023: 37 · 2022: 59 · 2021: 54
- FWCI
- 30.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid-beta, anti-amyloid therapy, drug efficacy, clinical trials
- MeSH terms
- Alzheimer Disease, Humans, United States, United States Food and Drug Administration, Randomized Controlled Trials as Topic, Treatment Failure, Drug Approval, Medical Futility, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
